文献速递造血干细胞移植与细胞治疗

选择性JAK1抑制剂伊塔替尼治疗急性移植物抗宿主病的1期试验

A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease.
PubMed 文献 · Blood Adv · 2020-01-01

主要终点安全耐受性可评估,第28天总缓解率在200mg组为78.6%、300mg组为66.7%,初治和激素难治患者均有缓解,所有患者糖皮质激素用量随时间减少。

要点

  • 伊塔替尼200mg或300mg联合糖皮质激素在急性GVHD中耐受性良好,最常见非血液学不良事件为腹泻(48.3%)。
  • 第28天总缓解率200mg组78.6%、300mg组66.7%,初治患者75.0%、激素难治患者70.6%。
  • 所有接受伊塔替尼治疗的患者糖皮质激素用量随时间减少,提示具有激素节约效应。

核心结论

  • 伊塔替尼在初治或激素难治性急性GVHD患者中耐受性良好并显示出鼓舞人心的疗效,值得进一步临床研究。

研究设计与样本

  • 主要终点为安全性和耐受性,第28天总缓解率为主要次要终点。

主要发现

  • 报告1例剂量限制性毒性:300mg组1例既往血小板减少患者出现归因于GVHD进展的3级血小板减少。
  • 最常见非血液学治疗中出现的不良事件为腹泻(48.3%,n=14),贫血发生于11例患者(38%)。
  • 第28天总缓解率200mg组为78.6%,300mg组为66.7%。
  • 第28天总缓解率在初治急性GVHD患者中为75.0%,在激素难治患者中为70.6%。
  • 所有接受伊塔替尼治疗的患者糖皮质激素用量随时间减少。

临床怎么用

  • 对于异基因造血干细胞移植后发生IIB-IVD级急性GVHD的成人患者,伊塔替尼200mg或300mg每日一次联合糖皮质激素可作为探索性治疗选择。
  • 治疗期间需监测腹泻和贫血等不良事件,并注意血小板减少患者中GVHD进展相关的血液学毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute graft-versus-host disease (aGVHD) following allogeneic hematopoietic cell transplantation (HCT) is a primary cause of nonrelapse mortality and a major barrier to successful transplant outcomes. Itacitinib is a Janus kinase (JAK)1-selective inhibitor that has demonstrated efficacy in preclinical models of aGVHD. We report results from the first registered study of a JAK inhibitor in patients with aGVHD. This was an open-label phase 1 study enrolling patients aged ≥18 years with first HCT from any source who developed grade IIB to IVD aGVHD. Patients with steroid-naive or steroid-refractory aGVHD were randomized 1:1 to itacitinib 200 mg or 300 mg once daily plus corticosteroids. The primary endpoint was safety and tolerability; day 28 overall response rate (ORR) was the main secondary endpoint. Twenty-nine patients (200 mg, n = 14; 300 mg, n = 15) received ≥1 dose of itacitinib and were included in safety and efficacy assessments. One dose-limiting toxicity was reported (grade 3 thrombocytopenia attributed to GVHD progression in a patient receiving 300 mg itacitinib with preexisting thrombocytopenia). The most common nonhematologic treatment-emergent adverse event was diarrhea (48.3%, n = 14); anemia occurred in 11 patients (38%). ORR on day 28 for all patients in the 200-mg and 300-mg groups was 78.6% and 66.7%, respectively. Day 28 ORR was 75.0% for patients with treatment-naive aGVHD and 70.6% in those with steroid-refractory aGVHD. All patients receiving itacitinib decreased corticosteroid use over time. In summary, itacitinib was well tolerated and demonstrated encouraging efficacy in patients with steroid-naive or steroid-refractory aGVHD, warranting continued clinical investigations. This trial was registered at www.clinicaltrials.gov as #NCT02614612.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Schroeder MA, Khoury HJ, Jagasia M, et al. A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. Blood Adv. 2020. PMID: 32324888. doi:10.1182/bloodadvances.2019001043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。